公开(公告)号：DE50105229D1

公开(公告)日：2005-03-10

申请号：DE50105229

申请日：2001-05-12

Applicant: BASF AG

Inventor： KOLTER DR ,  FLICK DIETER ,  ASCHERL HERMANN

IPC: A61K47/32 ,  A61K9/16 ,  A61K9/20 ,  A61K9/22 ,  A61K47/04 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/26 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38 ,  A61K47/42 ,  A61P3/02

公开(公告)号：DE10029201A1

公开(公告)日：2001-12-20

申请号：DE10029201

申请日：2000-06-19

Applicant: BASF AG

Inventor： KOLTER KARL ,  FLICK DIETER ,  ASCHERL HERMANN

IPC: A61K47/32 ,  A61K9/16 ,  A61K9/20 ,  A61K9/22 ,  A61K47/04 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/26 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38 ,  A61K47/42 ,  A61P3/02 ,  A61K31/52

Abstract: Production of an oral dosage form (I) providing retarded active agent release, comprising: (a) a formulated mixture of polyvinyl acetate and polyvinyl pyrrolidone; (b) active agent(s); (c) optionally water-soluble polymers or lipophilic additives; and (d) optionally further conventional auxiliaries, involves granulating a mixture of (a), (b) and optionally (c) and/or (d) under heating at 40-130 degrees C. Production of an oral dosage form (I) providing retarded active agent release, comprising: (a) a formulated mixture of polyvinyl acetate (PVAc) and polyvinyl pyrrolidone (PVP); (b) active agent(s); (c) optionally water-soluble polymers or low or high molecular lipophilic additives; and (d) optionally further conventional auxiliaries, (e) involves granulating a mixture of (a), (b) and optionally (c) and/or (d) under heating at 40-130 degrees C. Independent claims are included for: (i) the obtained oral formulations (I); (ii) retarded release medicaments containing (I).